Health experts say that they are seeing a rare type of cancer therapy in clinical trial in North Carolina that is promising and promising but also raises questions about its safety.
“The type of the cancer that they’re seeing in the trials is very rare, so it’s a very promising study,” said Dr. Jennifer Llynosky, an oncologist at the University of North Carolina Health Science Center.
“I don’t think we’ve seen a cancer like this in human history.”
The study is in the early stages, but the study is set to begin on Wednesday.
Dr. Llynasky said the first phase of the study will look at using the drug for people with early stage cancer and then looking at the effects of taking the drug in people with more advanced cancers.
She said the new drug is being tested by the NCI.
In a news release, NCI said that it was pleased to be participating in a clinical trial of a novel oncologic chemotherapy drug, which is being evaluated by the U.S. Food and Drug Administration.
The FDA says the study results will be presented in a meeting in June.NCI spokeswoman Jennifer Llinasky says the FDA has not yet made any decisions about approving the new treatment for use in people over the age of 50.
The drug, called Bovine Tumor-3, has a very low half-life and can be administered within days of a tumor diagnosis.
It is being studied by the National Cancer Institute at the National Institutes of Health.
Llynasy said Bovigil could be helpful in patients with certain types of cancers.
It is a small molecule that is able to penetrate the tumor, and it does not have to be given in large doses, she said.
The NCI says the trial has not been approved by the FDA yet.
The company is hoping to make Bovogil available in the next few months.